Dev Vaz, MD
Cardiovascular Disease · Greenville, SCNPI 1174614804
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Lexicon Pharmaceuticals, Inc. at 56.2% of the total. Reporting peaked in 2024 at $8,928 and has fallen 89.2% since, to $967 in 2025.
Across 225 payments — averaging $62.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$8K
- Boston Scientific$749
- Medtronic$668
- Novartis$647
- Abbott$551
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$539
- plus $3K from 22 others
Across 14 payments — averaging $17,345 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$239K
- Abbott$4K
What the payments were for
- Speaking & faculty fees$7,74055%
- Travel & lodging$440%
- Food & beverage$6,13643%
- Education$2021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lexicon Pharmaceuticals, Inc. | 8 | $7,939 |
| Boston Scientific | 14 | $749 |
| Medtronic(2 entities) | 34 | $668 |
| Novartis | 39 | $647 |
| Abbott | 4 | $551 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $539 |
| Amgen | 18 | $461 |
| AstraZeneca | 10 | $410 |
| Abiomed | 3 | $289 |
| Philips North America LLC | 8 | $232 |
| Cvrx, Inc. | 4 | $219 |
| Edwards Lifesciences | 2 | $215 |
| Boehringer Ingelheim | 9 | $200 |
| E.r. Squibb & Sons, L.L.C. | 10 | $158 |
| Johnson & Johnson | 9 | $150 |
| Pfizer | 10 | $137 |
| Siemens Medical Solutions USA, Inc. | 1 | $120 |
| Novo Nordisk | 3 | $84 |
| Astellas Pharma US Inc | 1 | $70 |
| Amarin Pharma, Inc. | 3 | $63 |
| Atricure, Inc. | 3 | $56 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Merck | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inpefa$7,864
- Impella$250
- CARDIOMEMS$202
- CardioMEMS HF System$177
- Mitra Clip system$147
- Barostim Neo System$146
- WATCHMAN FLX$145
- Cobalt$126
- VIGILANT$123
- MAGNETOM Sola$120
- Farapulse$119
- Edwards SAPIEN 3 Transcatheter Heart Valve$119
- FARXIGA$114
- LifeVest$112
- Watchman$107
How this compares
$14,122 in reported general payments places this provider in the 85th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 566 | $555,707 |
| EntrestoSacubitril/Valsartan | 214 | $232,513 |
| Repatha SureclickEvolocumab | 175 | $121,443 |
| XareltoRivaroxaban | 84 | $85,272 |
| JardianceEmpagliflozin | 64 | $63,701 |
| FarxigaDapagliflozin Propanediol | 40 | $45,520 |
| Praluent PenAlirocumab | 25 | $15,296 |
| Metoprolol Succinate | 465 | $6,468 |
| Repatha SyringeEvolocumab | 11 | $6,201 |
| Ezetimibe | 170 | $5,168 |
| Rosuvastatin Calcium | 318 | $4,781 |
| Ranolazine ErRanolazine | 27 | $3,029 |
| Carvedilol | 389 | $2,406 |
| Torsemide | 123 | $2,024 |
| Losartan Potassium | 262 | $2,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $555,707566 claims |
| NovartisEntresto | $647 | $232,513214 claims |
| Johnson & JohnsonXarelto | $150 | $85,27284 claims |
| Boehringer IngelheimJardiance | $200 | $63,70164 claims |
| AstraZenecaFarxiga | $410 | $45,52040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Greenville
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Christopher SalmonGreenville$54K
- Arthur EberlyGreenville$34K
- Tara HolderGreenville$20K
- Jon BittrickGreenville$13K
- James MerriamGreenville$11K
- Harold BlanksGreenville$9K
- Arthur SiachosGreenville$9K
- Robert BiedermanCharleston$775K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.